^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Blenrep (belantamab mafodotin-blmf) (Microtubule inhibitor, BCMA-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/25/2020
Excerpt:
Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Source:
Published date:
08/05/2020
Excerpt:
BLENREP is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Source:
Title:
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
02/03/2021
Excerpt:
Recommendations: Patients at third and subsequent lines of treatment: For triple-class refractory patients, Sd or belantamab mafodotin monotherapy is recommended [II, B], if available.
DOI:
10.1016/j.annonc.2020.11.014
Source:
Excerpt:
Multiple Myeloma...Useful in ceratin circumstances…Belantamab mafodotin-blmf
Source:
Title:
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Published date:
10/05/2023
Excerpt:
Median follow-up was 11·5 months (5·5-17·6) for belantamab mafodotin and 10·8 months (5·6-17·1) for pomalidomide-dexamethasone. Median progression-free survival was 11·2 months (95% CI 6·4-14·5) for belantamab mafodotin and 7·0 months (4·6-10·6) for pomalidomide-dexamethasone (hazard ratio 1·03 [0·72-1·47]; p=0·56)...Belantamab mafodotin...statistically improved progression-free survival compared with standard-of-care, but there were no new safety signals associated with its use.
DOI:
10.1016/S2352-3026(23)00243-0
Trial ID:
Source:
Title:
FDA GRANTED ACCELERATED APPROVAL TO BELANTAMAB MAFODOTIN-BLMF FOR MULTIPLE MYELOMA
Published date:
08/15/2020
Excerpt:
...the US Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent....
